Industry Segment: Pharmaceutical & Biotech | Word Count: 67 Words

Oxford's COVID-19 vaccine human trials in Sao Paulo, Brazil are underway, and after an agreement with AstraZeneca, the government of Brazil is planning to acquire the first vaccine batches. Vaccine production will begin at the end of 2020 and the beginning of 2021. The total investment is $127 million, and it will be developed through Brazil's national pharmaceutical company, Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos.